Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreren
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Zwitserland
  4. Swiss Exchange
  5. Novartis AG
  6. Nieuws
  7. Persberichten
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Rapport
Geschatte realtime Cboe Europe  -  09:25:17 07-02-2023
79.86 CHF   +0.90%
06/02NOVARTIS AG : Berenberg blijft neutraal
MD
06/02Novartis' Sandoz Unit zegt dat US FDA Biologics License Application voor Osteoporosis Biosimilar Treatment heeft geaccepteerd.
MT
06/02Novartis zegt dat Sandoz's Prolia, Xgeva Biosimilar geaccepteerd is voor beoordeling in VS
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť NOVARTIS AG
06/02Novartis : ESG Update Q4 2022
PU
06/02Patients with hidradenitis suppurativa experienced sustained efficacy and symptom impro..
AQ
06/02Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US F..
GL
04/02Patients with hidradenitis suppurativa experienced sustained efficacy and symptom impro..
GL
01/02Novartis : Q4 Earnings Snapshot
AQ
01/02Novartis : Condensed financial report
PU
01/02Novartis : Annual Report 2022 (SIX filing)
PU
01/02Novartis : 2022 Financial Results
PU
01/02Novartis : The report
PU
01/02Novartis continues to grow with further core margin expansion and achieves important in..
GL
30/01Sandoz receives positive CHMP opinion for citrate-free high concentration formulation o..
GL
27/01Novartis : provides update on Phase III STAND trial assessing crizanlizumab
PU
24/01Sandoz announces agreement to acquire leading antifungal agent Mycamine from Astellas, ..
AQ
24/01Sandoz announces agreement to acquire leading antifungal agent Mycamineģ from Astellas,..
GL
11/01Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hu..
AQ
10/01China’s Porton to set up biotech park in Slovenia’s Menges
AQ
04/01CJEU Issues Guidance On When Parallel Importers Can Rebrand Generics As Branded Medicin..
AQ
2022An Arrow Through Declaratory Relief?
AQ
2022Case Analysis : Teva UK Ltd And Anor v Novartis AG And Anor
AQ
2022Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO, NEVANAC, VIGAM..
AQ
2022Novartis receives European Commission approval for Pluvicto as the first targeted radio..
AQ
2022Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational..
GL
2022Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
AQ
2022Novartis investigational iptacopan provides clinically meaningful increases in hemoglob..
GL
2022MorphoSys Out Licenses Pre-Clinical Oncology Program
AQ
2022Novartis Kisqaliģ prolonged PFS benefit for pre- and perimenopausal patients with aggre..
GL
2022Novartis PluvictoTM shows statistically significant and clinically meaningful radiograp..
GL
2022European Court Of Justice Issues Lan : No Repackaging/Rebranding As The Originator Referen..
AQ
2022Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study f..
AQ
2022Novartis : and Medicines for Malaria Venture announce decision to move to Phase 3 study fo..
PU
2022Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 da..
GL
2022New long-term Leqvioģ (inclisiran) data from Novartis show sustained efficacy and safet..
GL
2022Sandoz announces further investment in key manufacturing facility in Austria, to suppor..
GL
2022Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spe..
AQ
2022Biogen Seeks A Preliminary Injunction In Natalizumab BPCIA Case Against Sandoz
AQ
2022Novartis : Q3 Earnings Snapshot
AQ
2022Novartis : Financial Results – Q3 2022
PU
2022Novartis maintains growth momentum and confirms FY'22 Group guidance
GL
2022Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful ..
GL
2022Novartis : Q3 2022 Results Investor presentation
PU
2022Novartis receives positive CHMP opinion for Pluvictoģ for patients with progressive, PS..
GL
2022World Sight Day 2022 : Raising awareness on the importance of eye health
PU
2022Novartis : The FY 2021 Novartis environmental indicators (PDF 0.
PU
2022Malaria Pipeline Landscape Analysis of 15+ Companies by DelveInsight
AQ
2022Pm(noc) Regulations : Five-year Anniversary Of Major Amendments
AQ
2022Monsenso participates in new, large innovation project
AQ
2022Sandoz Granted Leave To Add New Allegations On Condition Of Trial Adjournment And Exten..
AQ
2022Novartis unveils new focused strategy, underpinned by eight potential multi-billion dol..
GL
2022Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenyaģ (f..
GL
2022Tysabriģ (Natalizumab) Litigation Begins
AQ
2022Sandoz announces further progress on its biosimilar pipeline, with release of positive ..
GL
2022Sandoz announces further progress on its biosimilar pipeline, with release of positive ..
AQ
2022Novartis statement regarding competition authority investigation into assertion of a pa..
GL
2022Biogen Files Sealed Complaint Against Sandoz And Polpharma Biologics Regarding Natalizu..
AQ
2022Novartis Hematology : Working to help ensure patients are getting the access they need
PU
2022Novartis : invests in early technical development capabilities for next-generation biother..
PU
2022Novartis Cosentyxģ shows clinically meaningful symptom improvements in patients with hi..
AQ
2022Novartis Cosentyxģ shows clinically meaningful symptom improvements in patients with hi..
GL
2022Novartis Kisqaliģ adds one more year of survival benefit for broadest set of patients, ..
GL
2022Novartis Hematology : Working to help ensure patients are getting the access they need
PU
2022Novartis highlights depth of immunology pipeline with novel data at key upcoming intern..
GL
2022The Sound Of Silence – The Importance Of Knowing What Your Invention Is Not
AQ
2022Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMe..
GL
2022Kaiku Health to improve cancer care through partnership with global medicines company
AQ
2022Novartis presents new data in breast and prostate cancer at ESMO
GL
2022Novartis looks at spinning out generics unit
AQ
2022Branaplam : VIBRANT-HD Study Update
PU
2022Swiss drugmaker Novartis to spin off generics unit Sandoz
AQ
2022Novartis announces intention to separate Sandoz business to create a standalone company..
GL
2022Novartis : Download the Novartis 2030 Environmental Sustainability Strategy
PU
2022Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant..
GL
2022Australia's Cell and Gene Catalyst moves ahead
AQ
2022Sandoz & Polpharma Announce FDA And EMA Acceptance Of Applications For Natalizumab Bios..
AQ
2022Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab acc..
GL
2022Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab acc..
AQ
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op NOVARTIS AG